.png){kind=logo}
A biotech company’s next research breakthrough is something a cyberattacker may want to steal, expose or hold for ransom. The appeal can extend beyond proprietary discoveries to the systems that keep research moving. That combination makes cybersecurity a strategic concern for biotech leaders evaluating whether their IT support aligns with the risks associated with their work.
For a biotech company, proprietary research can represent years of work before a product reaches the market. A stolen dataset could therefore expose much more than ordinary business information. Depending on the organization’s activities, sensitive holdings may include genomic research or clinical trial records, as well as confidential development plans.
These assets create different kinds of exposure. Research findings may interest parties seeking access to emerging technology, while identifiable patient information introduces privacy concerns. Security planning should aim to account for those differences rather than treating every file as equally sensitive. A system holding unpublished discoveries may warrant tighter access than a shared administrative workspace.
The National Institute of Standards and Technology (NIST) addresses this tension in its research security framework, which recognizes intellectual property theft and misuse as risks associated with international scientific collaboration. Its approach seeks to safeguard research while preserving open scientific exchange. Collaboration itself remains valuable, but the information exchanged deserves deliberate protection.
For biotech leaders, the practical question is how to enable useful access without extending it unnecessarily. A university partner may need selected research files without visibility into unrelated projects. Clear boundaries can support that distinction. The same sensitivity that makes information worth stealing can also give criminals leverage when they threaten to make it unavailable.
Ransomware adds an immediate operational problem to the risk of theft. When essential files become inaccessible, a biotech organization may have to suspend work that depends on them. Potential consequences extend to research schedules or production activities, depending on which systems are affected. An attack need not directly compromise a laboratory instrument to interrupt a dependent workflow.
The Federal Bureau of Investigation, U.S. Department of Health and Human Services (HHS), and Cybersecurity and Infrastructure Security Agency describe the Medusa threat as a ransomware-as-a-service variant in a joint federal advisory. Healthcare and Public Health appears among its intended-audience sectors. HHS joined the updated advisory specifically to contribute insight into Medusa’s operations against that sector.
According to the same Medusa ransomware advisory, attackers encrypt victims' data and threaten to publish stolen information. This double-extortion approach creates separate recovery and confidentiality problems. Restoring access does not, by itself, resolve the exposure created by an attacker’s copy of sensitive records.
That distinction matters for organizations handling both research and patient information. Recovery planning should consider whether essential work can resume safely, while incident response must also address what may have left the environment. The federal warning concerns the wider health sector, rather than establishing a biotech-specific attack rate, but it illustrates the pressure created when disruption accompanies threatened disclosure.
A biotech organization’s exposure can extend beyond its own staff accounts. External research partners may exchange datasets, while equipment suppliers may require remote support connections. Contract research organizations and cloud platforms add further relationships for security teams to evaluate. Each connection raises questions about who has access and how that access is controlled.
The Health Information Sharing and Analysis Center identifies accelerating supply chain exploitation as its most concerning trend in the 2026 Global Health Sector Threat Landscape Report. Its discussion highlights how weaknesses involving third parties can affect the organizations depending on them. Reviewing internal defenses alone therefore leaves an important part of the risk picture unexplored.
The practical response is closer scrutiny of external dependencies. Leaders can ask whether a supplier’s account remains active after its work ends, or whether a shared platform holds information beyond the project’s scope. Those questions connect third-party oversight to everyday research operations. They also help clarify what an IT partner should understand before recommending controls.
Routine troubleshooting addresses immediate technical problems, but biotech leaders also need to make decisions about research continuity and access to information. Support focused narrowly on resolving tickets may leave those broader decisions disconnected from the organization’s scientific priorities. Provider evaluation should therefore extend beyond how quickly someone answers a request.
A useful assessment considers whether a prospective partner understands the work that goes into the systems. For example, restoring a shared office application may involve different priorities from restoring access to an active research environment. The provider should be able to discuss those dependencies with scientific stakeholders and explain how its proposed approach reflects them.
Senior-level guidance can help turn those discussions into an ongoing plan. Leaders can evaluate how a provider assigns responsibility for recovery testing, and whether changes in research partnerships trigger a review of access. Life sciences experience offers a starting point for those conversations. A regional shortlist can then help organizations compare the support model against their specific environment.
The following providers are organized by region to help biotech organizations identify options near their research hubs. The selection reflects stated services rather than a comparative performance ranking.
For leaders evaluating the best IT services for Boston biotech companies, iuvo is a strategic consulting partner focused on New England life sciences organizations. Its Transformative IT Consulting connects technology decisions to business priorities, with life sciences work spanning digital lab enablement and compliance readiness through secure, scalable systems.
Its high-touch approach combines dedicated teams and senior guidance to support an ongoing relationship that develops alongside each client’s operations. The firm’s three-stage model moves through Discover & Define, Design & Enable, and Optimize & Evolve, providing a framework for planning improvements and revisiting technology needs as the business develops.
San Diego-based centrexIT serves the West Coast life sciences community, with IT leadership dating to 2002. Its stated capabilities include Food and Drug Administration (FDA) 21 CFR Part 11 compliance support and computer system validation for good laboratory, manufacturing and clinical practices.
Its data-integrity work incorporates ALCOA+ principles. For audit preparation, centrexIT reports that it helps dozens of life sciences organizations prepare for and pass FDA audits, a company-reported track record that prospective clients can discuss when assessing its suitability.
For New Jersey and the surrounding tristate area, Integrated Computer Services (ICS) is an independently owned firm headquartered in Glen Rock, New Jersey, that has operated since 2002. Its life sciences services include laboratory information management systems (LIMS) and electronic lab notebook support.
Its stated framework coverage extends to GxP good-practice requirements, FDA 21 CFR Part 11, the Health Insurance Portability and Accountability Act (HIPAA), and NIST cybersecurity frameworks. According to ICS, its business manages more than 10,000 endpoints and records 99% client retention, with 24/7 monitoring available.
Raleigh, North Carolina-based Petronella Technology Group has served clients since 2002 and offers services for Research Triangle Park organizations, including biotech and pharmaceutical firms. Its broader client base also includes defense-adjacent contractors, so its practice extends beyond life sciences.
The company lists HIPAA support and GxP validation assistance alongside Cybersecurity Maturity Model Certification (CMMC) readiness services. On its service page, Petronella Technology Group identifies itself as a CMMC Registered Provider Organization and advertises a Better Business Bureau A+ rating since 2003, with technical support extending to validated systems, LIMS and electronic lab notebooks.
Cybersecurity planning gives biotech leaders a way to examine how well technology supports the work their organizations need to protect. Research continuity and productive collaboration belong in that assessment, alongside the sensitivity of the information involved. The goal is a support model that reflects actual dependencies.
A practical next step is to compare existing IT support with the organization’s research environment. Leaders can ask how external access is reviewed and which systems receive priority during recovery. The strength of those answers can help distinguish a provider familiar with biotech’s working realities from one offering a standard service package.